15 December 2015
NovaMedica, a Russian pharmaceutical company, is starting construction of R&D Center for innovative drug development and pilot production in Moscow. This Center will include laboratories and production areas equipped with state-of-the-art process equipment that has never been used in the Russian pharmaceutical industry before. The total investments are estimated approximately $15 million.
18 June 2015
A Russian pharmaceutical company NovaMedica is planning to grow its R&D activities targeted at building a portfolio of proprietary nanotech-involving pharmaceutical products. This is what has been announced today by Vladimir Gurdus, General Manager at RMI Partners, managing company of NovaMedicw, at the Annual Saint Petersburg International Economic Forum during his panel discussion titled “Nanotechnologies – meeting the expectations?”
02 June 2015
NovaMedica, a Russian pharmaceutical company, and Ferring Pharmaceuticals, a Swiss-based global biopharmaceutical company, have signed an agreement, that gives NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market.
22 January 2015
Russian pharmaceutical company NovaMedica and Omega Pharma, a Belgium-based pan-European pharmaceutical company specializing in the development and sale of over-the-counter (OTC) health and personal care products, have signed a partnership agreement granting NovaMedica exclusive rights to promote, distribute and sell a line of OTC gastrointestinal products under the BenegastTM umbrella brand in Russia.
25 September 2014
NovaMedica LLC, a Russian pharmaceutical company, and Horus Pharma SL, a French company dedicated to the development of innovative products treating ophthalmic diseases, have signed a partnership agreement that grants NovaMedica exclusive rights to commercialize a portfolio of products in Russia and the Commonwealth of Independent States (CIS).
18 June 2014
“We have worked our way up from the concept of RusnanoMedInvest portfolio building to first sales of NovaMedica pharmaceutical company within two years’ time. This pace of development is considered fast in the pharmaceutical industry”, - Vladimir Gurdus, CEO, RMI Partners, Management Company of RusnanoMedInvest (RMI) and NovaMedica said during his speech at 20th Russian Pharmaceutical Forum in St. Petersburg.
04 June 2014
NovaMedica’s leader Fabrice Egros told Oksana Baranova, Pharmatsevtichesky Vestnik – Pharmaceutical Bulletin correspondent, about how the expats visualize and estimate prospects of the Russian pharmaceutical market.
23 May 2014
In general terms, engagement of private companies in the healthcare system on a competitive basis shall result in the price optimization and improvement of the quality of medical services provided and pharmaceuticals delivered to patients, Leonid Melamed, Chairman of the Board, Team Drive; Member of the Board of Directors, RusnanoMedInvest and NovaMedica said on Friday at St. Petersburg SPIEF2014.
25 March 2014
Leading Italian developer of innovative eye care solutions S.I.F.I. S.p.A. (SIFI) and Russian pharmaceutical company NovaMedica have entered into an exclusive commercial agreement for NovaMedica to market eight products developed and licensed by SIFI for the treatment of a wide range of ophthalmic pathologies in Russia and the CIS.
04 February 2014
NovaMedica Innotech, R&D unit of NovaMedica, a Russian pharmaceutical resident company of the Skolkovo Innovation Center, and Skolkovo Foundation signed the agreement to collaborate in building R&D center on the territory of Skolkovo Technopark.
18 February 2020
18 February 2020
17 February 2020
17 February 2020